INCYTE GENOMICS INC Form S-8 August 15, 2001

Registration No. 333-_____

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form S-8

REGISTRATION STATEMENT Under
THE SECURITIES ACT OF 1933

INCYTE GENOMICS, INC.

(Exact name of registrant as specified in its charter)

elaware

(State or other jurisdiction of

Incorporation or organization)

3160 Porter Drive Palo Alto, California

(Address of Principal Executive Offices)

94-3136539

(I.R.S. Employer Identification No.)

94304

(Zip Code)

1991 STOCK PLAN OF INCYTE GENOMICS, INC.

(Full title of the plan)

ROY A. WHITFIELD
Chief Executive Officer
Incyte Genomics, Inc.
3160 Porter Drive
Palo Alto, California 94304
(415) 855-0555

(Name, address and telephone number,

Copy to:
STANTON D. WONG, ESQ.
Pillsbury Winthrop LLP
P.O. Box 7880
San Francisco, CA 94120
(415) 983-1000

including area code, of agent for service)

CALCULATION OF REGISTRATION FEE

Title of Amount Proposed Maximum Proposed
Securities To To Be Offering Price Maximum Aggreg
Be Registered Registered(1) per Share(2) Offering Price

Common Stock, \$.001 par value(3) 2,500,000 shares \$17.10 \$42,750,000

- (1) Calculated pursuant to General Instruction E to Form S-8.
- (2) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(h)(1), based upon the average of the high and low sales prices of the Company's Common Stock on the Nasdaq National Market on August 13, 2001.
- (3) Associated with the Common Stock are Series A Participating Preferred Stock Purchase Rights that will not be exercisable or evidenced separately from the Common Stock prior to the occurrence of certain events.

The Registration Statement shall become effective upon filing in accordance with Rule 462 under the Securities Act of 1933.

INFORMATION REQUIRED PURSUANT
----TO GENERAL INSTRUCTION E TO FORM S-8

General Instruction E Information

This Registration Statement is being filed for the purpose of increasing the number of securities of the same class as other securities for which a Registration Statement of the Registrant on Form S-8 relating to the same employee benefit plan is effective.

Registrant's Form S-8 Registration Statements filed with the Securities and Exchange Commission on October 3, 2000 (File No. 333-47178), July 20, 1999 (File No. 333-83291), September 9, 1998 (File No. 333-63069), July 16, 1997 (File No. 333-31413), October 4, 1996 (File No. 333-13449), June 20, 1995 (File No. 33-93666) and on March 10, 1994 (File No. 33-76344) are hereby incorporated by reference.

Part II

Incorporation of Documents by Reference

The following documents previously filed by Registrant with the Commission are hereby incorporated by reference in this Registration Statement:

- (1) Registrant's Annual Report on Form 10-K (File No. 0-27488) for the fiscal year ended December 31, 2000;
- (2) Registrant's Quarterly Reports on Form 10-Q (File No. 0-27488) for the quarters ended March 31, and June 30, 2001;
- (3) Registrant's Current Report on Form 8-K filed on January 10, 2001, as amended by Form 8-K/A filed on February 5, 2001, and Current Reports on Form 8-K filed on February 13, and February 23, 2001 (File No. 0-27488);
- (4) The description of the Common Stock contained in Registrant's Registration Statement on Form 8-A filed January 5, 1996 (File No. 0-27488); and
- (5) The description of the Series A Participating Preferred Stock Purchase Rights contained in Registrant's Registration Statement on Form 8-A Filed September 30, 1998 (File No. 0-27488).

In addition, all documents subsequently filed by Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act of 1934 prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents.

EXHIBITS

Exhibit	
Number	Exhibit
5.1	Opinion of Pillsbury Winthrop LLP.
23.1	Consent of Ernst & Young LLP, Independent Auditors.
23.2	Consent of PricewaterhouseCoopers LLP, Independent Accountants.
23.3	Consent of PricewaterhouseCoopers LLP, Independent Accountants.
23.4	Consent of Pillsbury Winthrop LLP (included in Exhibit 5.1).
99.1	1991 Stock Plan of Incyte Genomics, Inc., as amended and restated (incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2001).

-1-

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8, and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Palo Alto, State of California, on August 14, 2001.

INCYTE GENOMICS, INC.

By /s/ ROY A. WHITFIELD

Roy A. Whitfield Chief Executive Officer (Principal Executive Officer)

POWER OF ATTORNEY

KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Roy A. Whitfield and John M. Vuko, and each of them, his true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments, including post-effective amendments, to this Registration Statement, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission granting unto said attorneys-in-fact and agents, and each of

them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys—in—fact and agents, or his substitute or substitutes, may do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the date indicated:

Signature

/s/ ROY A. WHITFIELD	Chief Executive Officer (Principal Executive Officer) and Director	August
Roy A. Whitfield	nacederive officer, and birector	
/s/ JOHN M. VUKO		August
John M. Vuko	rinancial Officer)	
/s/ TIMOTHY HENN	Controller (Principal Accounting Officer)	August
Timothy Henn		
/s/ JEFFREY J. COLLINSON	Director	August
Jeffrey J. Collinson		
-2-		
Signature	Title	
/s/ RANDAL W. SCOTT	Chairman of the Board	August
Randal W. Scott		
/s/ BARRY M. BLOOM	Director	August
Barry M. Bloom		
/s/ FREDERICK B. CRAVES	Director	August
-	Director	August
/s/ FREDERICK B. CRAVESFrederick B. Craves /s/ JON S. SAXE	Director	August August
/s/ FREDERICK B. CRAVESFrederick B. Craves		
/s/ FREDERICK B. CRAVES Frederick B. Craves /s/ JON S. SAXE	Director	

Title

-3-

INDEX TO EXHIBITS

Exhibit	
Number	Exhibit
5.1	Opinion of Pillsbury Winthrop LLP.
23.1	Consent of Ernst & Young LLP, Independent Auditors.
23.2	Consent of PricewaterhouseCoopers LLP, Independent Accountants.
23.3	Consent of PricewaterhouseCoopers LLP, Independent Accountants.
23.4	Consent of Pillsbury Winthrop LLP (included in Exhibit 5.1).
99.1	1991 Stock Plan of Incyte Genomics, Inc., as amended and restated (incorporated by reference to Exhibit 10.1 to the Company's Ouarterly Report on Form 10-0 for the quarter ended March 31, 2001).